Skip to main content
OpenTrials
Completed

NCT Number: NCT04526236

Influence of Aging on Perioperative Methadone Dosing

Increasingly, elderly patients undergo anesthesia and surgery. Methadone is a great opioid for perioperative pain management, however, to date there are no pharmacokinetic or pharmacodynamic studies that asses a methadone dose adjustment in the elderly patient. The present study is aimed to characterize the pharmacokinetic and pharmacodynamic age-related changes of methadone in the adult population and further to design reference dosing protocols for intraoperative methadone use according to patient age.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–105 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Pontificia Universidad Católica de Chile

Santiago, Santiago Metropolitan, 8320000, Chile

About this study

The subjects will be recruited from adult patients who undergo elective laparoscopic abdominal surgery at UC Christus Clinical Hospital (Santiago, de Chile). Patients will be randomly divided into four groups according to the dose of intravenous methadone to be administered during anaesthetic induction.

BIS-guided and standard general anaesthesia will be administered with routine monitoring. Methadone will be administered once the patient is intubated and has hemodynamic stability. The only opioids that patients will receive will be remifentanil and methadone.

Upon admission to the Post-anesthesia care unit, the patient is given a Patient-Control Analgesia pump for intravenous administration of morphine. Clinic evaluations will be carried out periodically and blood samples for measurement of plasma methadone will be taken at different times. Samples will be analyzed using high-performance liquid chromatography spectrofluorometric method. The data obtained will be collected in a form within the REDCAP application, to subsequently generate an encrypted database. Groups will be compared regarding pain score, drugs used, opioid consumption, side effects, time of recovery, and patient satisfaction.

One, two and three-compartment linear models will be used to fit the plasma methadone concentration data over time. Models are parameterized in terms of elimination clearance, compartment distribution clearance, central volume and peripheral volume of distribution, as appropriate. The use of rescue morphine in the Post-anesthesia care unit will be used as a measure to relate the methadone dose (mg/kg) with the analgesic efficacy using an EMAX model. The data will be modelled using NONMEM VII. A proportional term will be used for variability between subjects. Additive and proportional terms will be used to characterize the unknown residual variability.

Sample size calculations were estimated using a simulation-based approach and previous work with a similar methodology. To achieve an adequate representation of all age groups 60 patients will be required, distributed among 20 patients between 18 and 40 years, 20 patients between 41 and 65 years, and 20 patients> 65 years.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Over 18 years.
  • ASA I, II or III.
  • Laparoscopic Abdominal Surgery.

Exclusion criteria

  • BMI> 35
  • Use of opioids up to 5 days before surgery.
  • Acute Liver Failure or Chronic Liver Damage Child C.
  • Kidney damage with creatinine clearance estimated by Cockcroft-Gault formula <60 ml/min.

Treatment and study plan

Methadone Injectable Product

Drug

Perioperative use of placebo for pain management and remifentanil during the surgery.

Other names: Methadone 0, Methadone 1 0,05 mg/kg, Methadone 2 0,1 mg/kg, Methadone 3 0,2 mg/kg

Primary outcomes

  1. Methadone plasmatic levels Measured by high pressure liquid chromatography

    Time frame: From the first dose up to 24 hours.

    Five venous blood samples will be taken from each patient for methadone plasmatic level analysis. Patients will be randomly divided into two groups with different sample collection times. Group 1 at 0.05, 0.75, 1.5, 6, 18 hours post drug administration and Group 2 at 0.25, 1, 3, 12 and 24 hours.

Secondary outcomes

  1. Hemodynamics

    Time frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. Then, from the entrance to the recovery room every 30 minutes up to 180 minutes.

    Non invasive systolic and diastolic blood pressure monitoring (mmHg).

  2. Heart Rate

    Time frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. Then, from the entrance to the recovery room every 30 minutes up to 180 minutes.

    Heart rate (bpm)

  3. Pulse oximetry

    Time frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs. Then, from the entrance to the recovery room every 30 minutes up to 180 minutes.

    % oximetry saturation

  4. BIS

    Time frame: Every 5 min. Since entering operating room up to end of anesthesia and leaving to recovery room. In average 2 hrs.

    Depth of anesthesia will be recorded with BIS monitor. From 60 - 40

  5. Respiratory rate

    Time frame: Every 30 minutes. Since entering the recovery room up to 180 mins.

    bpm

  6. Numeric Pain Rating Scale

    Time frame: Every 30 minutes. Since entering the recovery room up to 180 mins.

    Numeric Pain rating scale in rest and movement, from 0 (no pain) to 10 (maximum pain).

  7. Nausea or vomiting

    Time frame: Every 30 minutes. Since entering the recovery room up to 180 mins.

    Presence of nausea or vomiting in the recovery room.

  8. Sedation (Ramsay Scale)

    Time frame: Every 30 minutes. Since entering the recovery room up to 180 mins.

    Ramsay scale (1-6)

  9. Respiratory depression

    Time frame: Every 30 minutes. Since entering the recovery room up to 180 mins.

    Presence of respiratory depression in the recovery room. (Respiratory rate less than 8 bpm requiring oxygen therapy).

  10. Other opioids and pain management drugs used during recovery stay

    Time frame: Since the admission to the recovery room up to 2 hours.

    Name and total doses, including Morphine PCA.

  11. Intestinal transit recovery

    Time frame: Since the admission to the recovery room up to 2 hours.

    Time to first flatus, fist bowel movement and stool. Presence of abdominal bloating.

Other outcomes

  1. Body fat

    Time frame: Once, before the anesthetic induction in the operating toom.

    Body fat (kilograms) by body impedance analysis.

  2. Level of satisfaction with pain management: 10-point scale

    Time frame: Since the admission to the recovery room up to 2 hours.

    10-point scale: very unsatisfied to very satisfied.

  3. Lean Mass

    Time frame: Once, before the anesthetic induction in the operating toom.

    Lean mass (kilograms) by body impedance analysis.

  4. Total water

    Time frame: Once, before the anesthetic induction in the operating toom.

    Total water (kilograms) by body impedance analysis.

Sponsors and collaborators

Lead sponsor

Pontificia Universidad Catolica de Chile

Other

Registry information

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Aug 25, 2020
Registry last updated
Dec 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.